Compare AbbVie Inc (ABBV) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? AbbVie Inc trades at $247.62 (market cap $441.94B), while JPMorgan Diversified Return International Eqty ETF trades at $76.97. The key difference: AbbVie Inc pays a 2.77% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | JPIN | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $77.00 |
52-Week Low | $197.38 | $64.96 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
JPIN (JPMorgan Diversified Return International Equity ETF) trades at $76.97, up 0.8% with strong technical momentum as moving averages signal bullish conditions. The ETF provides broad exposure to foreign large-cap value stocks through a smart beta approach. Recent dividend activity shows a $0.91 distribution scheduled for June 2026, while technical indicators show mixed signals with RSI in overbought territory but ADX confirming strong trend strength.
The ETF's outlook remains positive given its diversified international exposure and value orientation, though investors face currency risk and emerging market volatility. Current technical strength suggests continued upward momentum, but overbought RSI levels indicate potential near-term consolidation. The fund's systematic approach to international value investing provides defensive characteristics in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
